12,372 trials
Asthma
Primary: Postdose Strain-specific Hemagglutination-inhibition (HAI) Antibody Geometric Mean Fold Rise From Week 8 to Week 12 — 3.60; 3.13; 3.25; 3.85 Fold change
Bilateral Blepharospasm (BEB)
Primary: Double-blind MP: Change From Baseline in JRS Severity Subscore at Day 43 (Visit 4) — -0.6; -1.0; -1.8 score on a scale — p==0.0004
Plaque Psoriasis
Primary: Percentage of Participants With a ≥90% Improvement in Psoriasis Area and Severity Index (PASI 90) From Baseline — 42.2; 72.8 percentage of participants — p=<0.001
Breast Cancer · Musculoskeletal Complications · Pain
Primary: Average Joint Pain According to BPI-SF — 2.9; 3.5 units on a scale — p=0.0002
Chronic Scalp Psoriasis
Primary: Psoriasis Scalp Severity Index 90 (PSSI 90) — 52.9; 2.0 Percent of Participants — p=<0.001
Clostridium Difficile Infection
Primary: Adjusted Percentage of Participants With a Clinical Outcome of Cure at the End of Treatment (EOT) — 79.0; 83.6 Percentage of participants
Clostridium Difficile Infection
Primary: Adjusted Percentage of Participants Meeting Clinical Response Criteria for Cure at End of Treatment (EOT) — 83.4; 82.1 Adjusted percentage of participants
Colorectal Cancer Metastatic
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 769; 609; 272; 159 Participants
Complicated Intra Abdominal Infections
Primary: Death — 5; 5; 7; 1 Participants
Thrombocytopenia Associated With Liver Disease
Primary: Percentage of Participants Who Did Not Require a Platelet Transfusion After Randomization and up to 7 Days Following a Scheduled Procedure — 34.9; 68.6; 33.3; 87.9…
Homozygous Familial Hypercholesterolemia (HoFH)
Primary: The Number of Participants Who Experianced Adverse Events and Serious Adverse Events — 5 participants
Post-ERCP Acute Pancreatitis
Primary: The Number of Participants With Acute Pancreatitis After ERCP as Assessed by Worsening Abdominal Pain Plus Either Elevated Amylase or Lipase 3 x Upper Limit of Normal…
Chronic Lymphocytic Leukemia
Primary: Progression-Free Survival (PFS) — 21.8; 11.1 months — p=< 0.0001
Thrombocytopenia Associated With Liver Disease
Primary: Percentage of Participants Who Did Not Require a Platelet Transfusion or Any Rescue Procedure for Bleeding After Randomization Following a Scheduled Procedure — 22.9…
Non-small Cell Lung Cancer
Primary: Progression-Free Survival (PFS) Using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Investigator — 10.9; 1.4 months — p=<0.001